Highlights a distinct type of esophagitis caused by combined radiation and adriamycin/actinomycin D, characterized by a 'recall' phenomenon upon subsequent chemotherapy.
Answers are grounded in this paper and cite their sources.
Clinicians should recognize recall esophagitis risk with combined mediastinal radiation and these agents; case reports leave open incidence and prevention strategies.
With the increasing use of combined chemotherapy and radiotherapy in the treatment of certain types of malignancy, a clinically distinct type of esophagitis has been recognized as an undesirable side effect. It occurs with low doses (less than 2,000 rad) of mediastinal radiation in patients who simultaneously or sequentially receive either adriamycin or actinomycin D. Characteristic of this entity is "recall": recurrent episodes of esophagitis with each course of chemotherapy. The radiographic findings are nonspecific, ranging from subtle alterations in motility to severe damage with irreversible stricture formation. The primary differential diagnostic considerations are infectious processes. The radiographic spectrum, clinical aspects, and differential diagnoses in five patients are discussed.
No takes yet. Share an insight, caveat, or question.
Boal et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: